Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


Coverage Initiated on Firm Developing Gold Nanoparticle Therapy for Neurological Diseases
Research Report

Share on Stocktwits


The reasons Clene is a compelling investment are outlined in a ROTH Capital Partners report.

In a Feb. 3 research note, analyst Elemer Piros reported that ROTH Capital Partners initiated coverage on Clene Inc. (CLNN:NASDAQ) with a Buy rating and a 12-month price target of $24 per share; its current share price is $10.94.

Piros explained that the biopharma, based in Salt Lake City, Utah, develops therapeutics for neurodegenerative diseases. Its lead drug is CNM-Au8, a concentrated suspension of gold nanoparticles. Clene is developing the compound to "simultaneously address the bioenergetics deficit, oxidative stress and protein aggregation." In other words, the ultimate goal is to repair damaged neurons that result from neurodegenerative diseases.

The analyst provided the factors behind ROTH's Buy recommendation on Clene.

For one, CNM-Au8 catalyzes not just one but several functions. They include the production of energy-carrying adenosine triphosphate (ATP), "the reduction of harmful reactive oxygen species and elimination of toxic protein aggregates," Piros wrote.

Also, CNM-Au8 has potential in at least three disorders: Parkinson's disease and amyotrophic lateral sclerosis (ALS), in which it was shown to lower or eliminate protein aggregation in animal models, and multiple sclerosis, in which it was shown to reverse demyelination. In humans, CNM-Au8 has been shown to facilitate ATP production in the brain.

"In an early ALS and multiple sclerosis trial, signs of activity were seen indicating potential functional improvement and reversal of the course of disease," noted Piros, referencing a study in humans.

Finally, CNM-Au8 could be what Piros called a blockbuster or megablockbuster therapeutic.

"CNM-Au8 could achieve sales in excess of $1 billion in ALS and greater than $10 billion in a much larger multiple sclerosis indication, in our calculation," he wrote.

He indicated that Clene has other products in development, including CNM-AgZn17, a silver and zinc ion compound for infectious diseases and wound healing, and NM-PtAu7, a gold-platinum treatment for tumors.

With many shots on goal, Clene has numerous potential stock-boosting events happening this year and next, Piros pointed out, since it has four different Phase 2 clinical trials and one pivotal study now in progress. Those catalysts include topline data from the RepairPD imaging Phase 2 trial expected in H1/21 and from the RepairMS imaging Phase 2 trial anticipated in H2/21. Also this year, Clene should provide an update on the COVID-19 clinical program with CNM-AgZn17 in Brazil.


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the decision to publish an article until three business days after the publication of the article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of None, a company mentioned in this article.

Disclosures from ROTH Capital Partners, Clene Inc., Company Note, February 3, 2021

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

ROTH makes a market in shares of Clene, Inc. and Apellis Pharmaceuticals, Inc. and as such, buys and sells from customers on a principal basis.

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe